Chime Biologics, a leading global CDMO that enables its partners' success in biologics, today announced its continued ...

The revolutionary BiVACOR heart device was moved to Phase 2 of FDA trials after success in five human patients.

A new inhalable gene therapy for cystic fibrosis (CF) has entered Phase I clinical trials, a major milestone on the journey ...

The Phase II portion is seeking to establish safety and efficacy of the company’s HER2 breast cancer therapy in combination ...

A promising new mRNA-based vaccine for pancreatic cancer has shown potential in reducing the recurrence of the disease post-surgery. MSK's phase 1 cli ...

NEWARK, CA / ACCESS Newswire / February 21, 2025 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today reported financial results for the fourth quarter and full year ended ...

Tremfya was administered subcutaneously for both induction and maintenance, inducing a clinical response in 65% of moderate ...

The field of central nervous system (CNS) drug development is awash with activity. And major new centres of research are ...

Tremfya could become the first IL-23 inhibitor with fully subcutaneous induction and maintenance options in the treatment of ...

(formerly JNJ-2113) milestone earned in Q4 2024, received in January 2025PN-881, a potential best-in-class oral IL-17 receptor antagonist peptide nominated as a development candidate ...